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Behçet’s disease (BD) is a multisystemic disorder with an unknown etiology. Even
though autoimmunity is thought to play a part in the etiopathogenesis of BD, there
is no clear evidence to support this hypothesis.
1 This multisystemic involvement
might be a clue for the autoimmune pathogenesis. 
The presence of immunoreactans in the skin is either diagnostic or it helps the
diagnosis of some autoimmune diseases.
2-7 The aim of this study is to evaluate
immunoreactans depositions in BD using direct immunofluorescence (DIF), thus
implicating the autoimmune theory which we think is important in the etiopatho-
genesis of the disease. We compared the data of BD both with systemic lupus
erythematosus (SLE), which is an autoimmune disease as well as with healthy
controls.
A total of 164 skin samples from 108 BD and 36 SLE patients as well as 20
healthy controls were examined for depositions of immunoglobulin (Ig)M, IgG,
IgA, complement 3 (C3), and fibrinogen (F) using DIF. The Behçet’s Disease
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Purpose: Behçet’s disease (BD) is a disease of unknown etiology, which has multisystemic involvement. This
multisystemic involvement might be the clue for an autoimmune pathogenesis. In order to evaluate an autoimmune
pathogenesis, we examined immunoreactans depositions in the skin of BD patients. Materials and Methods: The
skin samples of 108 BD patients (28 perilesional skin, 44 positive pathergy test site, 22 negative pathergy test site,
14 normal skin) were examined for the depositions of immunoglobulin (Ig)M, IgG, IgA, complement 3 (C3), and
fibrinogen (F) using direct immunofluorescence (DIF). The data were statistically compared to the DIF of 36
systemic lupus erythematosus (SLE) patients and 20 healthy controls using χ 2 Fisher exact test. Results: Highly
significant immunoreactans depositions were obtained in BD (deposition rates: IgM 70.3%, IgG 0%, IgA 20.3%, C3
62.9%, F 83.3%). The comparison with SLE revealed no differences in IgM, IgA, and C3. However, IgG deposition
was higher in SLE while F deposition was higher in BD. In both BD and SLE, the Ig depositions were highly
significant when the data were compared with the healthy controls. Conclusion: The significant deposition of
immunoreactans in BD, especially in the negative pathergy and the normal skin sites, were observed. This study is
the first controlled study revealing positive Ig depositions in BD, and it is expected to help us to reconsider the
autoimmune pathogenesis in BD.
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Study Group (BD-SG) consisted of 108 randomly selected
patients, all fulfilling the International Study Group (ISG)
criteria,
13 who were admitted to our Behçet’s disease clinic
between the years 1996 - 2002. There were 65 female and
43 male patients. The mean age was 33.8 years range, (15 -
57 years). The mean duration of the disease was 8.1 years
range, (1 - 34 years). The biopsy materials were taken
from normal skin, 1 cm away from the defined lesion in all
study groups. In the 28 cases with mucocutaneous lesions,
the biopsies were preferably performed 1 cm away from
the uninvolved skin of sun-unexposed skin lesion. Punch
biopsy specimens were obtained from 28 lesional skin site
(15 oral aphthae, 9 pseudofolliculitis, 3 Sweet-like erup-
tions, and 1 erythema nodosum), 44 positive pathergy
reaction sites, 22 negative pathergy reaction site, and 14
normal skin site were obtained from the back. The
specimens were frozen with Thermo Shandon
® cryomatrix
frozen specimen embedding medium and 4 µ sections
were obtained (CM 1900, Lecia Microsystems GmbH
®,
Wetzlar, Germany). Fluorescein antihuman (FITC) IgM,
IgG, IgA, C3, and F conjugates (DakoDenmark A/S
®,
Glostrup, Denmark) were used to detect immunoreactans
depositions under immunofluorescein microscope (Zeizz_
axioskop MC 63
®M 35 W, Carl Zeiss MicroImaging GmbH,
Jena, Germany) with DIF technique.
One of the two control groups consisted of 36 SLE
patient (the systemic lupus study group = SL-SG), selected
randomly from the patients referred to the immunology
laboratory of our clinic for lupus band test between the
years 1996 - 2002. There were 29 female and 7 male patients
with a mean age of 34.3 years range, (15 - 67 years). The
mean duration of the disease was 7.6 years (1 - 29 years).
The second control group consisted of 20 patients who were
admitted to our clinic during the same period with lesions
of the skin or mouth but no systemic disease was revealed
with histopathologic and clinical examination (the healthy
study group = H-SG). There were 16 female and 4 male
patients with a mean age of 40.6 years range, (10 - 73 years).
The samples taken from sun-unexposed normal skin on the
back in the SL-SG and H-SG were examined for immuno-
reactans depositions using DIF. The data of the study
groups were compared to each other with χ 2 Fisher exact
test, and p value was calculated. The sites of depositions
with each immunoreactans were examined in all groups.
The 108 cases in BD-SG were classified into two groups
during three-month period of time before and after the
biopsies were taken, in a total six months period according
to the clinical condition as activity remissions. The patients
were carefully classified according to criteria indicated below.
Activation criteria 
Recurrences of the mucocutaneous lesions 3 - 4 times
and/or addition of a new type of systemic involvement
and/or addition of the mucocutaneous manifestations for
the first time and/or continuous arthritis and arthralgias
and/or addition of the systemic involvement for the first
time in a one-month period of time.
Remission criteria 
Absence occurrence of the mucocutaneous manifestations
1 - 2 times in a one-month period time and/or shortening of
the remissions period of the present mucocutaneous
lesions, or disappearing of the symptoms and/or disap-
pearing of the symptoms and signs of current systemic
involvement and/or presence of arthralgia(s) attacks for 1 -
2 times.
The 108 cases of BD-SG were compared according to
the clinical course of activity or remissions as DIF (+) and
DIF (-) using χ 2 Fisher exact test. Besides, 108 cases of
BD-SG were classified into two groups according to age
and gender; the differences between these groups were
defined as DIF (+) and DIF (-). χ 2 for trend test for age,
and χ 2 test for gender were used.
The sera of BD-SG and control group patients were not
investigated for autoantibodies and immunoreactans.
The clinical findings of the BS-SG are summarized in
Table 1. One hundred and eight Behçet’s disease patients
were enrolled in this study. The SL-SG consisted of 36
patients and the H-SG consisted of 20 patients. The immu-
noreactans depositions of the BD-SG according to the
RESULTS
Table 1.Clinical Findings of the BD-SG (n = 108)
Oral aphthae 108
Genital ulcerations 96
Erytema nodosum 72
Pseudofolliculitis 75
Thrombophlebitis 18
Ophtalmic involvement 14
Neurologic involvement 6
GIS involvement 3
Arthritis 23
Arthralgia 33
Extragenital ulcerasyon 7
Pathergy positive 87
Pathergy negative 16
HLA B5 (+) 42
HLA B5 (-) 10
HLA not performed 56
BD-SG, Behçet’s disease study group.sample sites and the site of depositions are listed in Table 2
and Table 3, respectively. The depositions of all compo-
nents were detected, except for IgG. In the BD-SG, the com-
parison of immunoreactans depositions in different sample
sites (perilesional skin, positive and negative pathergy sites,
normal skin) revealed no significant difference (Table 2).
When the data of the BD-SG were compared to the data
of the SL-SG, the IgG depositions was highly significant
for the SL-SG (p < 0.0001), while the F deposition was
highly significant for the BD-SG (p < 0.0001). There were
no differences in IgM, IgA, and C3 depositions neither in
the BD-SG nor in the SL-SG (Table 4).
In the H-SG, nine depositions were detected. Two of
them were detected as cytoid bodies with IgM, one of them
was a perivascular deposition with F, and six of them were
granular deposition of C3 in the dermoepidermal junction.
When the BD-SG was compared to the H-SG, deposi-
tions in all of the components were highly significant in
the BD-SG. When the SL-SG was compared to the H-SG,
the depositions were highly significant in the SL-SG
(Table 4).
The immunoreactans were deposited either in the peri-
vascular region (P), or in the dermoepidermal junction
(DEJ), or in both of them (P + DEJ). In the BD-SG, the
most frequent deposition was in the P (84%) which was
higher with F than with IgM (Fig. 1). The deposition in the
DEJ was in a granular band pattern, only with C3 (9%)
(Fig. 2). This deposition in the DEJ was sometimes seen
together with the P deposition (7%) (Fig. 3, Table 3).
The highest deposition rate in the SL-SG was in the DEJ
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Table 2.Immunoreactans Depositions according to the Sample Sites in the BD-SG
Immunoreactans types
IgM IgG IgA C3 F
Sample
Lesional skin* (n = 28) 20 0 7 16 25
Normal skin (n = 14) 12 0 2 5 13
Positive pathergy site (n = 44) 30 0 12 32 36
Negative pathergy site (n = 22) 14 0 1 15 16
Total (n = 108) 76 (70%) 0 22 (20%) 68 (63%) 90 (83%)
χ 2 Fisher exact test pvalue 0.53 - 0.14 0.07 0.32
BD-SG, Behçet’s disease study group.
*Lesional skin side: 15 oral aphthae. 9 pseudofolliculitis. 3 Sweet like eruptions. 1 erythema nodosum.
Table 4.Comparison of the DIF Findings of BD-SG with the DIF Findings of the SL-SG and H-SG
Immunoreactans types
IgM IgG IgA C3 F
Study groups
BD-SG (n = 108) 76 0 12 68 90
SL-SG (n = 36) 29 12 11 27 16
pvalue p= 0.28 p< 0.0001 p= 0.25 p= 0.22 p< 0.0001
BD-SG (n = 108) 76 0 22 68 90
H-SG (n = 20) 2 0 0 6 1
pvalue p< 0.0001 p= 0.02 p = 0.003 p< 0.0001
SG-SG (n = 36) 29 12 11 27 16
H-SG (n = 20) 2 0 0 6 1
pvalue p< 0.0001 p= 0.004 p= 0.004 p = 0.001 p= 0.002
BD-SG, Behçet’s disease study group; SL-SG, systemic lupus erythematosus study group; H-SG, healthy study group; DIF, direct
immunofluorescence.
Table 3.Location of the Immunoreactans Depositions in the BD-SG
Immunoreactans types
IgM IgG IgA C3 F Total
Site of deposition
P 76 0 22 27 90 215 (84%)
DEJ - 0 - 23 - 23 (9%)
DEJ + P - 0 - 18 - 18 (7%)
Total 76 0 22 68 90 256 (100%)
BD-SG, Behçet’s disease study group; P, perivascular; DEJ, dermoepidermal junction.with 84.1% (56.8% only in the DEJ, 27.3% together with
P deposition).
The distribution of immunoreactants in the active and
remitting groups of 108 BD-SG cases were classified
according to the material type and are shown in Table 5.
There was no statistically significant difference in the 4
different lesion types between the distribution of immuno-
reactants and activity of the disease (p> 0.05, Table 5).
There was no statistically significant difference in the
distribution of immunoreactants considering age (Table 6)
and gender (Table 7) patterns (p> 0.05).
In this study, immunoreactants depositions were examined
in the perilesional skin, pathergy test sites (positive and
negative) and normal skin of patients with BD, using DIF.
In literatures, it is advised to take the materials from the
normal skin. Moreover, the deposition of immunoreactants
in the sun-exposed areas has been shown to be more than
non-sun-exposed skin.
20-22 For this reason, we paid a great
deal of  attention to this point in the study. However, since
the patergy test was applied over the forearms on a sun-
exposed area, the results of the immunoreactants depositions
obtained from these areas are doubtful. Nevertheless, there
is little doubt as the rates of immunoreactants depositions
were not statistically different in the other materials (non-
lesional skin of Behçet’s disease cases and lesional skins).
The DIF studies of the BD in the literature are available for
us which done on small groups without control groups.
8-12
In 1976, Haim et al.
8 could not find any depositions with
IgA, IgG, IgM, IgE, C3, C4, albumin and fibrinogen in the
specimens of 18 BD patients, obtained from the pathergy
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Fig. 1. Perivascular depositions with fibrinogen (×40).
Fig. 2. Granular depositions with C3 in the dermoepidermal junction (×100).
Fig. 3. Perivascular and granular depositions with C3 in the dermoepidermal
junction (×10).
Table 5.Distribution of the Immunoreactants Depositions according to the Clinical Activation in BD-SG
Immunoreactans types
IgM IgG IgA C3 F
Sample
Lesional skin, n = 28 A, n = 21 16 0 5 13 18
R, n = 7 4 0 2 3 7
χ 2 Fisher exact test pvalue 0.37 - 1 41 0.55
Normal skin, n = 14 A, n = 6 5 0 2 2 6
R, n = 8 7 0 0 3 7
χ 2 Fisher exact test pvalue 1 - 0.16 1 1
Negative pathergy site, n = 22  A, n = 8 4 0 1 4 5
R, n = 14 10 0 0 11 11
χ 2 Fisher exact test pvalue 0.38 - 0.36 0.34 0.62
Positive pathergy site, n = 44 A, n = 18 14 0 7 13 14
R, n = 26 16 0 5 19 22
χ 2 Fisher exact test pvalue 0.33 - 0.18 0.06 0.69
BD-SG, Behçet’s disease study group; A, active; R, remission.
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reaction sites. In 1977, however, Azizlerli et al.
9 found
depositions in the pathergy test sites of seven BD patients
out of eight (4 with IgM, two with IgG, 1 with IgM, IgG,
and C3).
In 1981, Luderschmidt et al.
10 studied DIF of the oral
aphthae of 34 BD patients and found depositions with C3
and C1q in 30 patients, and perivascular deposition with
IgM and IgG in 8 patients. The deposition with C3 was
reported to be a band-like granular pattern. The author
concluded that oral aphtha was an immune complex
vasculitis.
10 In 1983, Reimer et al.
11 studied a group of nine
BD patients, and reported C3 deposition in the oral aphthae
of the nine BD patients, and IgM depositions in three of
them.
In our previous study in 1994, a group of 58 BD patients
were examined with DIF and histopathological findings
were compared. The samples were taken from perilesional
skin, positive and negative pathergy sites, and normal skin.
The rates of depositions were 70% for IgM (n = 41), 22.4%
for IgA (n = 13), 65.5% for C3 (n = 38), 81% for F (n =47),
and vasculitis was found histologically in 52 patients of 58
(89.6%), in which there was a leucocytoclastic type in
70.6% of them. Both DIF and the histopathologic manifes-
tations were in accordance with each other.
12
Alpsoy et al. performed a study in 2003 similar to our
study in 1994,
12 in which they found statistical significance
in both IgM depositions (p < 0.05) and histopathologically
leucocytoclastic vasculitis (p < 0.05) in the papulopustular
lesions.
23
Comparing the DIF results of Alpsoy with our 28 BD-
SG cases, we obtained deposition of IgM in 20 cases
(71.4%) against 52.9% rate reported by Alpsoy. Although
we did not found any IgG deposition, Alpsoy et al. found
35.3%.
23
It is highly likely that the higher rates of the mucosal
lesions (15 cases with aphthous lesions) made this differ-
ence, since 9 patients of  28 cases had pseudofollculitis.
However, considering the data of the 108 cases, absence of
any statistical difference in the skin and the type of the
lesion between the immunoreactants depositions weakens
this doubt (Table 2).
In the present study, we detected significant immunoreac-
tants depositions in four different lesion sites of our 108
BD patients (Table 2). When the depositions were compared
according to the lesion site, no significant difference was
detected. Especially, the similar data of depositions in the
lesional skin and positive pathergy site, compared to the
negative pathergy site and normal skin is an important
observation, pointing out possible immunologic mechani-
sms in the pathogenesis of BD. To our best knowledge,
this is the first report that evaluated the immunoreactants
depositions in the normal skin and the negative pathergy
sites of BD patients.
When the immunoreactants depositions of BD patients
were compared to the depositions in the non-sun-exposed,
uninvolved skin sites of SLE patients, there was no signifi-
cant difference in the deposition rates between the two
groups (p > 0.05). There were significant depositions with
Table 7.Immunoreactants Types-Gender Matching in BD-SG
Immunoreactans types
IgM IgG IgA C3 F
Gender
Female, n = 65 45 0 11 40 5
Male, n = 43 31 0 11 28 31
Chi Square test χ 2 = 0.01
-
χ 2 = 0.72 χ 2  = 0.03 χ 2 = 0.12
p= 0.91 p= 0.39 p= 0.86 p= 0.72
BD-SG, Behçet’s disease study group; SL-SG, systemic lupus erythematosus study group; H-SG, healthy study group; DIF, direct
immunofluorescence.
Table 6.Immunoreactants Distribution according to the Age Groups in BD-SG
Immunoreactans types
IgM IgG IgA C3 F
Age groups
11 - 20, n = 5 4 0 1 4 5
21 - 30, n = 34 25 0 6 22 31
31 - 40, n = 42 34 0 8 28 33
41 - 50, n = 23 14 0 6 13 17
51 - 60, n = 4 4 0 1 1 4
Chi Square for trend χ 2 = 0.09 - χ 2 = 0.47 χ 2 = 2.17 χ 2 = 2.10
p= 0.76 p= 0.49 p= 0.14 p= 0.14
BD-SG, Behçet’s disease study group; SL-SG, systemic lupus erythematosus study group; H-SG, healthy study group; DIF, direct
immunofluorescence.Afet Akdag Kose
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IgM, IgA, and C3 in both groups. Additionally, the F depo-
sition was higher in BD than in SLE (p < 0.0001). Because
SLE is an autoimmune disease with well known DIF find-
ings,
14-19 the depositions of IgM, IgA, and in C3 BD, which
were detected as much as in SLE is suggestive of the
immunologic pathogenesis in BD.
The comparison of the results of both BD and SLE
groups with the results of healthy controls revealed signifi-
cant deposition rates in the first two groups (Table 4). This
data confirm the finding of immunoreactants depositions
in BD, and it is not incidental.
In the literatures, there are no DIF studies performed in
healthy cases. Mostly, DIF was performed in normal patient
skins. Also in these studies, the rates of depositions in sun-
exposed areas were higher than the non-sun-exposed
areas.
20-22 There was no proven disease based on the clinical
findings, except using the immunofluorescence and histo-
pathological analyses in 20 cases (H-SG). The depositions
of C3 were found in 6 cases (30%), F in one (5%), and IgM
in 2 (10%) of patients. Comparing our data with the control
group of follicular acneiform lesions in the study of
Alpsoy, we find the most deposition of C3 in 6 cases
(30%); although this rate was 17.6% in Alpsoy’s study.
The IgM and fibrinogen deposition rates were 10% and
5% in our study and 17.6% and 17.6% in Alpsoy’s study,
respectively. Except C3, the other deposition rates in
Alpsoy’s study are higher than the ones in our study.
23 If we
think of technical errors in this study, as it is a controlled
research, the same technical error would occur in all groups,
therefore, our results seem to be believable.
The autoantibodies in the sera of patients were not detect-
ed in this study. If these components were also searched, it
would possibly be a better guide in BD etiopathogenesis.
As a result, in this study, the significant deposition of
immunoreactants in BD in four different groups lesions
(lesional skin, positive and negative pathergy sites, and
normal skin) was an important observation. This data were
compared to the depositions in SLE patients and healthy
controls to find out its significance. Thus, the autoimmune
mechanisms in the etiopathogenesis of BD should be
reconsidered, even though it currently lost some interest.
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